On a magic taxi ride. Well, you don't know what we can see. Why don't you tell your dreams to me. Fantasy will set you free...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pretty amazing, 1 year ago Juice WRLD was working at a factory. Now he has a track in the top 10, he's headlining with Tekashi69 and he's just been signed to a $3Mil contract with Interscope. Thats starpower there. This parnership with Nine Mile Entertainment is paying off in spades for $IMTV as far as A-list star connections. That's the way you make $ in this biz. Great for $IMTV investors.
HoD .0023. Nice vol. Get ready for the move to Green.
Your ignoring the fact that a month ago we were at .0003. The month chart looks great regardless if we have a little bit of churn here and there. Every thing takes a breather now and then when climbing a steep hill. But this is far from over. July 28th LIT Up Music Festival happening with A list hip hop talent. Plenty of unveils related to the the concert coming up. This is headed to copper land IMHO.
$PACV next week should be good.
Agreed. $PACV posting some nice indicators. NIce play unfolding here.
Agreed. Bounce is inevitable. And as more immuno oncology therapy developments come we need to look for that uplisting too.
Bit of a slow Friday afternoon. We've been plagued by little swing traders. Tiny bloodsucking gnats. They enter in on the churning. They like to take their $50 profits on the weekends for beer money. But they are missing the really lucrative vision here. The real money will be made here LONG.
As more testing results are finalized, i. e. OXS 1550, a fresh round of private funding would make sense. The IP and patents here are hot.
Not exactly happy to end under $2. Lets see if there are any last minute trades here for $GTBP.
Will we ever see $BTC at 10K again? or has this pump had the final dump?
$PLM looks like it could sustain about $1 as support.
I'm long and strong. Not interested in $50 flips. This is worth way more with a little patience. But I would recommend to anyone to average down and take advantage of any pullbacks. You'll be glad you did in a little while. Trust me. ;-D
This is the GTBP loading zone. It wont go much lower. If I was swing trading here I would make a nice little pile here as it churns somewhat regularly from 2 up to near 3. But I'm long and strong. The rewards here are much bigger for strong hands.
Agreed. Some chuckleheaded swings with crumbly fingers might be selling for some weekend beer money, but there are far too many prescient whales/longs built in here who know what they are holding and know this is going back above 3 very soon.
We are almost back at HoD now.
Strong news on the 11th: GT Biopharma Announces Preliminary Clinical Results From Interim Review of Phase 1/2 Clinical Trial of OXS-1550, its Bi-Specific Antibody Drug Conjugate
PR Newswire
LOS ANGELES, June 11, 2018
LOS ANGELES, June 11, 2018 /PRNewswire/ --
Clinical benefit observed in more than 50% of patients that met evaluation criteria
Efficacy signal most pronounced in relapsed/refractory acute lymphocytic leukemia patients (ALL) with clinical benefit in 75% (three of four) of evaluable patients
Adverse events mostly grade 1 or 2 and reversible
Expect additional ALL patients enroll in this trial
GT Biopharma, Inc. (GTBP) and (Euronext Paris: GTBP.PA) (the "Company"), an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary platforms, today announced preliminary clinical data taken from an interim review, or snapshot, of the OXS-1550 Phase 1/2 trial following a Bi-Specific Antibody Drug Conjugate (ADC) Advisory Board meeting and follow up discussions. OXS-1550 is a bi-specific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin, its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor, the CD22 receptor or both receptors.
OXS-1550 is being evaluated in an open-label, two-stage, investigator-led, Phase 1/2 trial at the Masonic Cancer Center, University of Minnesota. The trial has two arms including patients diagnosed with relapsed/refractory B-cell lymphomas (NHL) and leukemias (ALL). Eighteen patients have been enrolled to date, including 12 NHL and six ALL patients. At the time of the interim review, 13 patients met the evaluation criteria, including nine NHL and four ALL patients.
At the interim review more than 50% of patients (seven of 13) exhibited a clinical benefit, defined as stable disease plus partial response or complete remission at Day 29. Of the seven patients, one demonstrated a complete remission (CR), one demonstrated a partial response (PR) and five demonstrated stable disease (SD).
The efficacy signal was most prominent in ALL patients with 75% (three of four) exhibiting clinical benefit including one CR, one PR and one SD. In the NHL population, four of nine patients exhibited SD. Adverse events were mostly grade 1 and 2 and reversible. One patient had a grade 4 low platelet count, two patients had a grade 3 increase in liver function tests, or LFTs, and one patient had a grade 3 capillary leak.
GT Biopharma's President and Chief Medical Officer (CMO) Dr. Raymond Urbanski said: "In light of these data and discussions with the Bi-Specific ADC Advisory Board, I am increasingly encouraged by OXS-1550 and its potential to have a significant role in an oncologist's armamentarium. I also remain convinced that the bi-specific ADC platform has the potential to generate additional attractive product candidates. I look forward to continuing to work closely with the University of Minnesota team and other members of the Bi-Specific ADC Advisory Board with the goal of optimizing next steps for this program and the broader bi-specific ADC platform."
The Bi-Specific ADC Advisory Board has recommended that additional ALL patients be enrolled in the trial followed by another interim data review. The Company currently expects final data for this trial to be available in the fourth quarter of 2018 or the first quarter of 2019.
The Bi-Specific ADC Advisory Board is composed of distinguish clinicians, academics and researchers from several well-known institutions. Members include Dr. Jeffrey Miller, Deputy Director at the Masonic Cancer Center, University of Minnesota and Chair of GT Biopharma's Scientific Advisory Board. Dr. Veronika Bachanova, hematologist/oncologist and the principal investigator of the Phase 1/2 study and Dr. Daniel Vallera, lead researcher for the bispecific ADC program, both at the Masonic Cancer Center. Also included are Drs. Mark Litzow and Arthur Frankel. Mark R. Litzow, M.D., is Professor of Medicine in the Division of Hematology at Mayo Clinic. Arthur E. Frankel, M.D., is the inaugural holder of the Arlene and Mayer Mitchell Endowed Chair in Medical Oncology, Chief of Medical Oncology at Mitchell Cancer Institute (USA-MCI), Interim Associate Director for Basic & Translational Sciences and Professor of Oncological Sciences.
About GT Biopharma, Inc.:
GT Biopharma, Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms. GT's lead oncology drug candidate, OXS-1550 (DT2219) is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GT's TriKE platform will address a number of cancer types. GT's nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (neurology and pain) and shepherding them through the approval process to the Food and Drug Administration's New Drug Application. GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the progress and outcome of the Company's clinical trials and the likelihood of regulatory approval and commercialization of the Company's products. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to successfully complete its clinical trials and obtain regulatory approval and accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Westwicke Partners
John Woolford
+1(443)213-0506
john.woolford@westwicke.com
SOURCE GT Biopharma, Inc.
Long and strong on $GTBP . This share lockup and the rest of the results from OXS 1550 testing will push this up to 5 before 2019 IMHO.
Yes all this churning is planking in major support for the push to the leg up to 3. Coming very soon on $GTPB.
Thats some vital confirmation of the Immuno Oncology approach. Great for $GTBP!
$GTBP will leave its mark on the summer of 2018. The time is ripe. Immuno oncology is the next logical evolution in the history of cancer treatment.
HOD 2. 38. 2.50 will be an important resistance . $3 will be easy after that.
Agreed. There is no way to know yet publicaly but it surely seem that the OXS 1550 Phase 2 results must be strong for this share lockup to be agreed upon heading into the summer.
GTBP looking to see $3 as we get into summer here.
$BIOAQ forewarned is forearmed.
$3 seems within range at this rate. $GTBP rocking and rolling.
Looks like $GTBP is coming in for another nice green close here. Breakout week we are having!
$GTBP still holding on to a 25% gain nearing end of day.
Good find. Thats some good insight to chew on.
Good find. Thats some good insight to chew on.
Venezuela cant be ignored for sure.
$TOPS wow! up 50%? whats driving this?
$SUNW having a decent day but this board is dead?
RSHN up 40% great day!
Looking for another strong finish today $GTBP.
THIS NEWS WAS LIKE A ROCKET FOR $GTBP: GT Biopharma Announces Voluntary Lock-Up Agreements With Insiders Covering Over 52% of Outstanding Shares
PR Newswire
LOS ANGELES, June 5, 2018
LOS ANGELES, June 5, 2018 /PRNewswire/ --
GT Biopharma Inc. (OTCQB: GTBP) (Euronext Paris: GTBP.PA) or the "Company", an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary platforms, announces that the officers, non-independent directors of the Company and a significant founding shareholder of GT Biopharma's predecessor companies have entered into lock-up agreements in respect of approximately 52% (26 million) of the issued and outstanding common shares of the Company, effective immediately.
The voluntary lock-up Agreement stipulates that these shareholders will not offer to sell, contract to sell or otherwise dispose of any securities, or enter into any transaction to such effect, directly or indirectly, in addition to other restrictions, on or before September 31, 2019.
"By entering into the lock-up agreements, our executive team and certain large shareholders are reaffirming our belief in the vision of the Company and commitment to being aligned with our key stakeholders," said GT Biopharma's CEO, Shawn Cross.
About GT Biopharma, Inc.
GT Biopharma, Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms. GT's lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GT's TriKE platform will address a number of cancer types. GT's nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
$GTBP Blue Sky Breakout! $3 coming right up!
Shorties are running cover! $GTBP breakout!
BANG! $GTBP is on fire this week!
Nice progress made today in $GTBP on the march to $4.
Its always nice to get more than you asked for. $GTBP is bound to keep overdelivering for her investors.